4.86
price up icon1.67%   0.08
after-market 시간 외 거래: 4.94 0.08 +1.65%
loading

Immuneering Corp 주식(IMRX)의 최신 뉴스

pulisher
Mar 19, 2026

Immuneering Corp Stock (ISIN: US45255L1089) Faces Short-Term Pressure Amid Clinical Momentum and Ana - AD HOC NEWS

Mar 19, 2026
pulisher
Mar 17, 2026

Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival - Bitget

Mar 17, 2026
pulisher
Mar 17, 2026

New MEK approach in 64 cancer patients shows fewer resistance mutations - Stock Titan

Mar 17, 2026
pulisher
Mar 13, 2026

X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention - AOL.com

Mar 13, 2026
pulisher
Mar 12, 2026

Immuneering (IMRX) to Release Earnings on Thursday - MarketBeat

Mar 12, 2026
pulisher
Mar 09, 2026

Piper Sandler cuts Immuneering stock price target on launch timing - Investing.com

Mar 09, 2026
pulisher
Mar 07, 2026

Why Immuneering Corporation stock could outperform in 2026Earnings Growth Report & Community Supported Trade Ideas - Naître et grandir

Mar 07, 2026
pulisher
Mar 07, 2026

Immuneering (NASDAQ:IMRX) Raised to Hold at Wall Street Zen - MarketBeat

Mar 07, 2026
pulisher
Mar 07, 2026

Immuneering Corporation Q4 & Full Year 2025 Earnings: EPS Beats -$0.18 Estimate - Bayelsa Watch

Mar 07, 2026
pulisher
Mar 06, 2026

Oppenheimer reiterates Immuneering stock rating on pipeline progress - Investing.com

Mar 06, 2026
pulisher
Mar 06, 2026

Immuneering 2025 10-K: $0 Revenue, $(1.27) EPS and $(56.0)M Net Loss - TradingView

Mar 06, 2026
pulisher
Mar 06, 2026

Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - The Manila Times

Mar 06, 2026
pulisher
Mar 06, 2026

Immuneering Corporation Reports 64% Overall Survival in Phase 2a Trial for First-Line Pancreatic Cancer and Outlines 2026 Development Plans - Quiver Quantitative

Mar 06, 2026
pulisher
Mar 03, 2026

Immuneering to Present at the Leerink Global Healthcare Conference - The Manila Times

Mar 03, 2026
pulisher
Mar 02, 2026

Late-stage cancer firm Immuneering to outline pipeline at Miami investor event - Stock Titan

Mar 02, 2026
pulisher
Feb 28, 2026

IMRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Feb 28, 2026
pulisher
Feb 28, 2026

Immuneering Touts 64% 12-Month Survival for Atebimetinib in Pancreatic Cancer, Eyes Phase 3 - Yahoo Finance

Feb 28, 2026
pulisher
Feb 27, 2026

IMRX Should I Buy - Intellectia AI

Feb 27, 2026
pulisher
Feb 26, 2026

Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Feb 26, 2026
pulisher
Feb 26, 2026

Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of “Moderate Buy” by Brokerages - Defense World

Feb 26, 2026
pulisher
Feb 23, 2026

Merger Talk: Does Immuneering Corporation outperform in volatile marketsJuly 2025 Market Mood & Reliable Volume Spike Alerts - baoquankhu1.vn

Feb 23, 2026
pulisher
Feb 21, 2026

Investment Report: Does Immuneering Corporation meet Warren Buffetts criteriaPortfolio Update Summary & AI Based Trade Execution Alerts - baoquankhu1.vn

Feb 21, 2026
pulisher
Feb 19, 2026

Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - The Manila Times

Feb 19, 2026
pulisher
Feb 18, 2026

Immuneering Corporation to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Quiver Quantitative

Feb 18, 2026
pulisher
Feb 18, 2026

Oncology company Immuneering to detail pipeline, strategy at virtual Oppenheimer event - Stock Titan

Feb 18, 2026
pulisher
Feb 01, 2026

Sanofi Invests $18.96 Million in Immuneering Corporation $IMRX - MarketBeat

Feb 01, 2026
pulisher
Feb 01, 2026

Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Feb 01, 2026
pulisher
Jan 29, 2026

What is Immuneering Corporation’s valuation compared to sector2025 Performance Recap & Long-Term Safe Investment Plans - mfd.ru

Jan 29, 2026
pulisher
Jan 22, 2026

Empery Asset Management, LP Reduces Stake in Immuneering Corp - GuruFocus

Jan 22, 2026
pulisher
Jan 22, 2026

Thomas Schall Buys 21,645 Shares of Immuneering (NASDAQ:IMRX) Stock - Defense World

Jan 22, 2026
pulisher
Jan 21, 2026

Immuneering (NASDAQ:IMRX) Insider Harold Eugene Brakewood Purchases 5,250 Shares of Stock - MarketBeat

Jan 21, 2026
pulisher
Jan 21, 2026

Immuneering’s (IMRX) chief business officer buys $24,990 in stock By Investing.com - Investing.com Australia

Jan 21, 2026
pulisher
Jan 21, 2026

Immuneering’s (IMRX) chief business officer buys $24,990 in stock - Investing.com

Jan 21, 2026
pulisher
Jan 20, 2026

Insider Buying: Immuneering (NASDAQ:IMRX) Director Purchases 21,645 Shares of Stock - MarketBeat

Jan 20, 2026
pulisher
Jan 20, 2026

Immuneering director Schall buys $101k in shares By Investing.com - Investing.com India

Jan 20, 2026
pulisher
Jan 20, 2026

Immuneering director Schall buys $101k in shares - Investing.com

Jan 20, 2026
pulisher
Jan 19, 2026

Immuneering Corporation (NASDAQ:IMRX) Short Interest Update - Defense World

Jan 19, 2026
pulisher
Jan 17, 2026

Immuneering Corporation (NASDAQ:IMRX) Sees Significant Growth in Short Interest - MarketBeat

Jan 17, 2026
pulisher
Jan 16, 2026

Insider Buying: Brett Hall Acquires Additional Shares of Immunee - GuruFocus

Jan 16, 2026
pulisher
Jan 16, 2026

Hedge Fund and Insider Trading News: Ken Griffin, Bill Ackman, Michael Burry, Warren Buffett, Aurelius Capital Management, Balyasny Asset Management, Jain Global, Saba Capital Management, Bain Capital, Immuneering Corp (IMRX), Cloudflare Inc (NET) - Insider Monkey

Jan 16, 2026
pulisher
Jan 16, 2026

Director of Immuneering Picks Up 1.8% More Stock - Yahoo Finance

Jan 16, 2026
pulisher
Jan 16, 2026

Insider Buying: Leah Neufeld Acquires Additional Shares of Immuneering Corp (IMRX) - GuruFocus

Jan 16, 2026
pulisher
Jan 15, 2026

Immuneering chief people officer Neufeld buys $10,905 in IMRX By Investing.com - Investing.com Nigeria

Jan 15, 2026
pulisher
Jan 15, 2026

Immuneering chief people officer Neufeld buys $10,905 in IMRX - Investing.com

Jan 15, 2026
pulisher
Jan 15, 2026

Looking Into Immuneering Corp's Recent Short Interest - Sahm

Jan 15, 2026
$99.29
price up icon 1.20%
$27.80
price up icon 0.00%
$52.37
price down icon 0.06%
$89.31
price down icon 0.77%
$144.00
price up icon 0.91%
biotechnology ONC
$282.72
price up icon 0.15%
자본화:     |  볼륨(24시간):